Press Releases

Press Releases

or

May 12, 2021
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--May 12, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results from its broad hematology program will be presented
May 6, 2021
Recorded product revenue of $106.1 million for the first quarter, compared to $52.1 million in the prior year period Included in China’s National Reimbursement Drug List (NRDL), effective March 1, 2021 , significantly driving increased demand for tislelizumab, BRUKINSA ® , and XGEVA ® Closed
April 28, 2021
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Apr. 28, 2021-- BeiGene (NASDAQ: BGNE; HKEX: 06160) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA ® (zanubrutinib) against ibrutinib in adults with relapsed or refractory (R/R) chronic
March 30, 2021
Current CFO and Chief Strategy Officer Howard Liang , Ph.D. to Retire from BeiGene in June CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Mar. 30, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines, today